Abstract
Background18F-FDG PET/CT metabolic parameters have been applied as prognostic factors in multi-malignancies. However, the role in locally advanced pancreatic cancer (LAPC) was not confirmed. In this study, we investigated the prognostic value of 18F-FDG PET/CT metabolic parameters in LAPC patients treated with stereotactic body radiation therapy (SBRT).MethodsSeventy three LAPC patients who received SBRT therapy and pre-treatment 18F-FDG PET/CT imaging from January 2012 to January 2016 were included in this retrospective study. The study aim was to evaluate the relationship between metabolic parameters with clinical factors, and the value of metabolic parameters in the prognosis of LAPC. The median of parameters was set as the cut-off value for statistical analysis. Univariate survival analysis was performed by the Kaplan Meier method and log-rank test, and multivariate analysis was carried out by a Cox proportional hazards model.ResultsPatients with lymph node metastasis or longer tumor diameters were associated with higher TLG (P < 0.05). Univariate analysis showed MTV, TLG, radiotherapy dose and chemotherapy were significantly associated with disease progression-free survival (PFS) and overall survival (OS) (P < 0.05). Lymph node metastasis and tumor longest diameter were associated with OS. Multivariate analysis demonstrated TLG, radiotherapy dose, and chemotherapy were independent factors of PFS and OS (HR: 2.307, 0.591, 0.572 and 2.145, 0.480, 0.471, P < 0.05).ConclusionsTLG was found to be the independent prognostic factor of OS and PFS. Among clinical factors, radiotherapy dose and chemotherapy were independent prognostic factors of OS and PFS.
Highlights
18F-FDG PET/CT metabolic parameters have been applied as prognostic factors in multi-malignancies
The median progression-free survival (PFS) time was 9.7 months, only one case presented with censored data in PFS, who showed no evidence of disease progression by the end of follow-up
In the Multivariate analysis, for locally advanced pancreatic cancer (LAPC) patients treated with stereotactic body radiation therapy (SBRT) by Cyberknife, total lesion glycolysis (TLG), radiotherapy dose and chemotherapy were demonstrated as the independent prognostic factors for overall survival (OS) and PFS
Summary
18F-FDG PET/CT metabolic parameters have been applied as prognostic factors in multi-malignancies. The role in locally advanced pancreatic cancer (LAPC) was not confirmed. We investigated the prognostic value of 18F-FDG PET/CT metabolic parameters in LAPC patients treated with stereotactic body radiation therapy (SBRT). Methods: Seventy three LAPC patients who received SBRT therapy and pre-treatment 18F-FDG PET/CT imaging from January 2012 to January 2016 were included in this retrospective study. The study aim was to evaluate the relationship between metabolic parameters with clinical factors, and the value of metabolic parameters in the prognosis of LAPC. About 20–40% of patients are diagnosed with locally advanced pancreatic cancers (LAPC), whose median survival period was 6–14 months. Of the 40–45% of pancreatic cancer patients who present with distant metastases, the median survival time was only 3–6 months [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
